MA39219B1 - Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique - Google Patents
Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophiqueInfo
- Publication number
- MA39219B1 MA39219B1 MA39219A MA39219A MA39219B1 MA 39219 B1 MA39219 B1 MA 39219B1 MA 39219 A MA39219 A MA 39219A MA 39219 A MA39219 A MA 39219A MA 39219 B1 MA39219 B1 MA 39219B1
- Authority
- MA
- Morocco
- Prior art keywords
- alzheimer
- lateral sclerosis
- amyotrophic lateral
- lrrk2 kinase
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des nouveaux composés qui inhibent l'activité de la kinase lrrk2, des procédés liés à leur préparation, des compositions les contenant, et leur utilisation dans le traitement ou la prévention de maladies caractérisées par une activité de la kinase lrrk2, par exemple, la maladie de parkinson, la maladie d'alzheimer et la sclérose latérale amyotrophique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014000139 | 2014-01-29 | ||
PCT/CN2015/000055 WO2015113452A1 (fr) | 2014-01-29 | 2015-01-28 | Composés |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39219A1 MA39219A1 (fr) | 2017-09-29 |
MA39219B1 true MA39219B1 (fr) | 2018-11-30 |
Family
ID=53756224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39219A MA39219B1 (fr) | 2014-01-29 | 2015-01-28 | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique |
Country Status (20)
Country | Link |
---|---|
US (2) | US10087186B2 (fr) |
EP (1) | EP3099695B1 (fr) |
JP (1) | JP6422986B2 (fr) |
KR (1) | KR20160106622A (fr) |
CN (1) | CN105940004B (fr) |
AU (2) | AU2015210593A1 (fr) |
CA (1) | CA2937431A1 (fr) |
CL (1) | CL2016001895A1 (fr) |
CR (1) | CR20160348A (fr) |
DO (2) | DOP2016000195A (fr) |
EA (1) | EA029774B1 (fr) |
ES (1) | ES2802174T3 (fr) |
IL (1) | IL246579B (fr) |
MA (1) | MA39219B1 (fr) |
MX (1) | MX367370B (fr) |
PE (1) | PE20161443A1 (fr) |
PH (1) | PH12016501307B1 (fr) |
SG (1) | SG11201605342UA (fr) |
UA (1) | UA118369C2 (fr) |
WO (1) | WO2015113452A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10339791B2 (en) | 2007-06-12 | 2019-07-02 | Icontrol Networks, Inc. | Security network integrated with premise security system |
WO2017156493A1 (fr) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Composés, compositions et procédés |
PE20161443A1 (es) | 2014-01-29 | 2017-01-06 | Glaxosmithkline Ip Dev Ltd | Compuestos |
WO2015113451A1 (fr) | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Composés |
CN105153131B (zh) * | 2015-09-21 | 2017-10-17 | 马彦丽 | 一种在护理上治疗人神经胶质瘤的药物组合物 |
CN105348270B (zh) * | 2015-11-09 | 2018-01-09 | 吕显艳 | 一种防治牙体牙髓感染的药物组合物 |
US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
JP2018537502A (ja) | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼlrrk2阻害剤としての使用、及びその調製方法 |
CN105418616B (zh) * | 2015-12-26 | 2018-01-12 | 山东大学 | 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用 |
CN109311857B (zh) | 2016-06-16 | 2021-11-12 | 戴纳立制药公司 | 作为用于治疗神经退化性病症的lrrk2抑制剂的嘧啶-2-基氨基-1h-吡唑 |
CN110446700A (zh) * | 2017-01-25 | 2019-11-12 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
KR20180097162A (ko) | 2017-02-22 | 2018-08-30 | 국립암센터 | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
ES2930106T3 (es) * | 2017-03-23 | 2022-12-05 | Daegu Gyeongbuk Medical Innovation Found | Compuesto derivado de pirrol-piridina, procedimiento para preparar el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o el tratamiento de enfermedades relacionadas con la proteína quinasa |
US11370796B2 (en) | 2017-12-05 | 2022-06-28 | Oscotec Inc. | Substituted pyrazoles as LRRK2 inhibitors |
CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
WO2020036437A1 (fr) * | 2018-08-16 | 2020-02-20 | 재단법인 대구경북첨단의료산업진흥재단 | Dérivé hétéroaryle substitué, son procédé de production, et composition pharmaceutique destinée à prévenir ou à traiter des maladies liées à la protéine kinase le contenant en tant que principe actif |
US11130752B2 (en) * | 2018-09-25 | 2021-09-28 | Cardurion Pharmaceuticals, Llc | Aminopyrimidine compound |
CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
KR20230091150A (ko) * | 2020-10-29 | 2023-06-22 | 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 | 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도 |
WO2023076404A1 (fr) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Méthodes de traitement de lupus érythémateux disséminé |
AR127470A1 (es) | 2021-10-27 | 2024-01-31 | H Lundbeck As | Inhibidores de lrrk2 |
TW202412777A (zh) | 2022-09-15 | 2024-04-01 | 丹麥商H 朗德貝克公司 | 富白胺酸重複激酶2(lrrk2)抑制劑 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004274403A1 (en) | 2003-09-03 | 2005-03-31 | Aventis Pharmaceuticals Inc. | 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
ES2393926T3 (es) | 2004-10-21 | 2013-01-02 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Gen KASPP (LRRK2), su producción y uso para la detección y tratamiento de trastornos neurodegenerativos |
WO2006050076A1 (fr) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Composes de pyrrolyle fusionnes substitues par pyrimidinyle et utiles dans le traitement des troubles induits par la kinase |
NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
TW200800215A (en) | 2005-10-13 | 2008-01-01 | Glaxo Group Ltd | Novel compounds |
EP2024342A2 (fr) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Composés hétérocycliques 2-amino-substitués à cycles fusionnés |
WO2009036066A1 (fr) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Inhibiteurs du récepteur du facteur de croissance endothélial vasculaire (vegfr) contenant une fraction de liaison au zinc |
US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
WO2009143018A2 (fr) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Composés et procédés de modulation des kinases, et indications associées |
WO2009143404A1 (fr) | 2008-05-23 | 2009-11-26 | Wyeth | Pipérazine utilisée en tant que modulateurs allostériques négatifs agissant sur le récepteur métabotropique du glutamate de type 5 (mglur5) |
CA2760794C (fr) | 2009-05-05 | 2017-07-25 | Dana Farber Cancer Institute | Inhibiteurs d'egfr et procedes de traitement de troubles |
MX2012003778A (es) * | 2009-09-29 | 2012-06-01 | Glaxo Group Ltd | Compuestos novedosos. |
WO2011153553A2 (fr) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Méthodes et compositions pour l'inhibition de kinases |
WO2012009258A2 (fr) | 2010-07-13 | 2012-01-19 | Edward Roberts | Modulateurs des récepteurs à la galanine peptidomimétiques |
WO2012045195A1 (fr) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines à titre d'inhibiteurs de fak et d'alk pour le traitement des cancers et autres maladies |
SG189043A1 (en) | 2010-11-10 | 2013-05-31 | Hoffmann La Roche | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2651404B1 (fr) | 2010-12-14 | 2015-10-14 | Electrophoretics Limited | Inhibiteurs de caséine kinase 1 delta (ck1delta) |
WO2012143144A1 (fr) | 2011-04-21 | 2012-10-26 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases |
MX2014003501A (es) | 2011-09-22 | 2014-07-22 | Pfizer | Derivados de pirrolopirimidina y purina. |
JP6148248B2 (ja) * | 2011-11-30 | 2017-06-14 | ジェネンテック, インコーポレイテッド | Lrrk2のポジトロン放出断層撮影(pet)イメージングのためのフッ素−18及び炭素−11標識放射性リガンド |
GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
CN104271578B (zh) | 2012-05-03 | 2016-09-14 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
RU2637947C2 (ru) | 2012-05-03 | 2017-12-08 | Дженентек, Инк. | Производные пиразоламинопиримидина в качестве модуляторов обогащенной лейциновыми повторами киназы 2 |
EA025186B1 (ru) * | 2012-06-29 | 2016-11-30 | Пфайзер Инк. | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 |
WO2015113451A1 (fr) | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Composés |
PE20161443A1 (es) | 2014-01-29 | 2017-01-06 | Glaxosmithkline Ip Dev Ltd | Compuestos |
-
2015
- 2015-01-28 PE PE2016001250A patent/PE20161443A1/es unknown
- 2015-01-28 SG SG11201605342UA patent/SG11201605342UA/en unknown
- 2015-01-28 CN CN201580006361.XA patent/CN105940004B/zh not_active Expired - Fee Related
- 2015-01-28 MX MX2016009893A patent/MX367370B/es active IP Right Grant
- 2015-01-28 MA MA39219A patent/MA39219B1/fr unknown
- 2015-01-28 EP EP15743797.1A patent/EP3099695B1/fr active Active
- 2015-01-28 AU AU2015210593A patent/AU2015210593A1/en not_active Abandoned
- 2015-01-28 KR KR1020167020367A patent/KR20160106622A/ko not_active Application Discontinuation
- 2015-01-28 CA CA2937431A patent/CA2937431A1/fr not_active Abandoned
- 2015-01-28 US US15/114,858 patent/US10087186B2/en not_active Expired - Fee Related
- 2015-01-28 ES ES15743797T patent/ES2802174T3/es active Active
- 2015-01-28 CR CR20160348A patent/CR20160348A/es unknown
- 2015-01-28 EA EA201691514A patent/EA029774B1/ru not_active IP Right Cessation
- 2015-01-28 UA UAA201609099A patent/UA118369C2/uk unknown
- 2015-01-28 JP JP2016549028A patent/JP6422986B2/ja not_active Expired - Fee Related
- 2015-01-28 WO PCT/CN2015/000055 patent/WO2015113452A1/fr active Application Filing
-
2016
- 2016-06-30 PH PH12016501307A patent/PH12016501307B1/en unknown
- 2016-07-03 IL IL246579A patent/IL246579B/en not_active IP Right Cessation
- 2016-07-26 CL CL2016001895A patent/CL2016001895A1/es unknown
- 2016-07-29 DO DO2016000195A patent/DOP2016000195A/es unknown
-
2018
- 2018-01-12 AU AU2018200277A patent/AU2018200277B2/en not_active Ceased
- 2018-08-02 US US16/052,791 patent/US10618901B2/en not_active Expired - Fee Related
-
2019
- 2019-01-15 DO DO2019000010A patent/DOP2019000010A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39219A1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
MA46018A (fr) | Activateurs d'édition du génome | |
MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
MA43335B1 (fr) | Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr | |
EA201792047A1 (ru) | Новые соединения | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA38284B1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
MA41179A (fr) | Composés inhibiteurs de parg | |
MA35246B1 (fr) | 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2 | |
MA44948A1 (fr) | Inhibiteurs de bace 1 | |
PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
EA202092086A1 (ru) | Ингибиторы аргиназы | |
MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
MA54133B1 (fr) | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y | |
MA37763A1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
GEP20227442B (en) | Boron containing pde4 inhibitors | |
EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
WO2015189830A9 (fr) | Composés inhibiteurs doubles utilisables dans le traitement de troubles neurodégénératifs et de la maladie d'alzheimer | |
MA45367B1 (fr) | Inhibiteurs de la tyrosine kinase | |
MA39260A1 (fr) | (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c | |
MA47097B1 (fr) | Compositions et procédés pour inhiber l'activité de l'arginase | |
EA202190690A1 (ru) | Борсодержащие ингибиторы pde4 | |
MA51297B1 (fr) | Quinazolinones en tant qu'inhibiteurs de parp14 | |
EA201990393A1 (ru) | Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств |